Spectrum Of Activity
500 mg IV q6h OR 1 g IV q8h
Meningitis: 2 g IV q8h
Infuse over 30 minutes
PNA < 14 DaysPNA ≥14 Days20 mg/kg/dose IV Q12H20 mg/kg/dose IV Q8H
PNA <14 DaysPNA ≥14 Days20 mg/kg/dose IV Q8H30 mg/kg/dose IV Q8H
The recommended dose is 40 mg/kg/dose
- Reconstitute 1 gram vial with 20mL of NS = 50 mg/mL
- Mix 4mL of 50 mg/mL concentration with 6mL of NS in a 10mL empty sterile vial = 20 mg/mL
50 mg/mL = 24H (after first use)
20 mg/mL = 24H
0 - 10 eGFR10 - 25 eGFR25 - 50 eGFR50+ eGFR500 - 1000 mg IV q24h500 - 1000 mg IV q12h500 - 1000 mg IV q8hNo dose adjustment required.
0 - 10 eGFR10 - 50 eGFR50+2 g IV Q24H2 g IV Q12HNo dosage adjustment required.
Increase dosing interval in renal impairment
Therapy of serious infections involving multi-drug resistant gram negative organisms.
Pregnancy: Limited published data in human pregnancies, however, due to the known safety of other beta lactams, meropenem is considered compatible in pregnancy.
Breastfeeding: Meropenem transfers into breastmilk in very small amounts and is not well absorbed orally. Two case reports published did not show any adverse events in two infants exposed to meropenem via breastmilk. Meropenem is given in therapeutic doses to infants. It is considered compatible with breastfeeding. Monitor the infant for any signs of gastrointestinal intolerance.
CBC if therapy prolonged
Immediate and delayed-type allergy
GI disturbance, cytopenias, positive Coombs
Liver enzyme abnormalities
Valproic acid - carbapenems decrease valproate levels and may decrease seizure threshold
Antimicrobial class: Carbapenem